Lilly Asia, Qiming, HongShan et al Double Down on Cell Therapy Tech
22 Oct 2024
US$ 19.00
Lilly Asia Ventures, Qiming Venture Partners, HongShan and FreesFund, all existing investors of XellSmart ......
Tag
Biotech
Related Publications
Listen to China Investments (Subscribers' Weekly 05 Dec 2025)...
Subscribers’ Weekly for the week ending 5 Dec 2025...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.